The COVID-19 pandemic highlighted the need for adaptable and scalable vaccine technologies. While mRNA vaccines have improved disease prevention, most are delivered by intramuscular injection, which may not effectively prevent infections that begin at mucosal surfaces, such as the nose and lungs. For respiratory pathogens, this limits protection at the initial site of infection.
Inhalable nanovaccines are being investigated as an alternative approach. These formulations are designed to activate immune responses in the respiratory tract, where pathogens often enter, by delivering antigens to local immune cells through mucosal immunization.
Mechanisms of Delivery: How Nanocarriers Work
Inhalable nanovaccines utilize engineered nanoparticles to deliver antigens or genetic material to immune cells in the respiratory tract. These nanocarriers are designed to overcome biological barriers, such as mucus layers and enzymatic degradation, while targeting antigen-presenting cells (APCs) like dendritic cells and alveolar macrophages to enhance immune activation.
Lipid Nanoparticles (LNPs)
LNPs, widely used in mRNA COVID-19 vaccines, are being adapted for inhalable delivery. Their formulation includes ionizable lipids, cholesterol, and polyethylene glycol (PEG), which protect messenger RNA (mRNA) and facilitate its uptake by cells.
A recent study in the Journal of the American Chemical Society demonstrated that modified LNPs remained stable during nebulization and successfully delivered mRNA to the lungs of mice, leading to uniform protein expression without inducing inflammation.1 An additional modification involving cationic lipids improved targeting of lung tissues.1,2
Polymer-Based and Biomimetic Systems
Polymeric nanoparticles, such as those made from polylactic-co-glycolic acid (PLGA), can be designed for controlled release and enhanced immune response. Researchers have also developed virus-like nanovaccines that mimic the structural features of pathogens.
One biomimetic COVID-19 vaccine combined pulmonary surfactant liposomes with SARS-CoV-2 spike proteins, promoting mucosal immunoglobulin A (IgA) responses in preclinical models. Similarly, mussel-inspired nanoparticles with mucoadhesive properties have shown promise in penetrating lung mucus to deliver anticancer drugs, a strategy adaptable for vaccines.3,4
Hybrid Nanoplatforms
Hybrid platforms combine synthetic and biological components to improve vaccine performance. One approach involved fusing nanovesicles expressing SARS-CoV-2 antigens with adjuvant-loaded liposomes. This formulation activated alveolar macrophages and led to the production of both systemic immunoglobulin G (IgG) and mucosal IgA, suggesting broader protection across different viral variants.5
Key Advantages of Inhalable Nanovaccines
Needle-Free Delivery
Inhalable vaccines avoid the risks associated with injections, including needle-related injuries and infections. They may also be more acceptable to people with needle phobia and are easier to administer in mass vaccination efforts. Convidecia Air, an inhalable COVID-19 vaccine approved in China, demonstrated high user acceptability.5
Inhalable formats could also support self-administration, which is especially relevant in regions with limited healthcare infrastructure.6
Unlike injectable vaccines, which mainly stimulate systemic IgG, inhalable vaccines promote the production of secretory immunoglobulin A (sIgA) at mucosal surfaces. sIgA helps neutralize pathogens before they can infect host cells, reducing transmission. A recent study published in Signal Transduction and Targeted Therapy showed that intranasal RNA vaccines can generate lung-resident memory T cells and sIgA, providing superior protection against respiratory viruses compared to intramuscular shots.2,6
Enhanced Stability and Distribution
Many nanovaccine platforms, including LNPs and polymer-based systems, can be freeze-dried (lyophilized), allowing storage at 4°C or lower without cold-chain dependency. For example, researchers at the University of Wisconsin-Madison developed a lyophilized avian influenza nanovaccine stable for 30 days at -20 °C, indicating its suitability for use in low-resource or remote settings.7
Current Research and Target Diseases
Recent advancements in inhalable nanovaccines are transforming disease prevention and treatment. Current targets include COVID-19, influenza, tuberculosis, and lung cancer.
COVID-19
Inhalable vaccine platforms have been applied extensively in COVID-19 research. Scientists have developed a hybrid nanovaccine that combines receptor-binding domain (RBD)-expressing nanovesicles with monophosphoryl lipid A (MPLA) adjuvant liposomes. This combination has been shown to elicit potent neutralizing antibodies against multiple variants, including Omicron, in preclinical models.
Additionally, a biomimetic vaccine designed to mimic the structure of the virus induced mucosal sIgA responses in mice that exceeded those generated by intramuscular vaccines.3,5
Influenza
Conventional influenza vaccines have limited efficacy due to frequent antigenic drift. Nanoparticle-based strategies aim to improve coverage by delivering conserved antigens or mosaic hemagglutinin (HA) proteins. A study from the University of Wisconsin–Madison developed a mosaic HA nanovaccine capable of eliciting cross-reactive immune responses in poultry against diverse high pathogenic avian influenza (HPAI) strains. This approach may be adaptable to human vaccination.7
Tuberculosis (TB)
TB primarily infects the lungs, making inhalable vaccines an ideal option. Studies have shown that PLGA nanoparticles loaded with Mycobacterium tuberculosis (Mtb) antigens can stimulate lung-resident immune cells, resulting in a greater reduction in bacterial load compared to injectable Bacillus Calmette-Guérin (BCG) vaccines.8
Lung Cancer
In addition to their potential for treating infections, inhalable nanovaccines are also being explored in oncology. Recent studies have shown that intranasal RNA vaccines encapsulated in lipid nanoparticles enhanced with cationic lipid 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) can reprogram cytotoxic T cells to target lung tumors in mice. This approach has doubled the survival rates in mice without causing systemic toxicity.2
Formulation Challenges and Innovations
Researchers are developing new strategies to address technical challenges associated with inhalable nanovaccine delivery, focusing on stability, lung retention, and immune safety.
Overcoming Mucosal Barriers
The lung’s mucus layer and mucociliary clearance rapidly remove inhaled particles. To address this, researchers developed nanoparticles with mucoadhesive surfaces, such as those coated with cysteine-modified mussel proteins, which prolong retention in the lungs.3
Stability During Nebulization
Nebulization can damage nanoparticles, reducing efficacy. A recent study published in the Journal of the American Chemical Society solved this by incorporating zwitterionic polymers into LNPs, which prevented aggregation and maintained mRNA integrity during aerosolization.1
Balancing Immunogenicity and Safety
While adjuvants such as MPLA enhance immune responses, excessive activation can lead to inflammation. Hybrid nanovaccines using pH-sensitive polymers have been developed to provide more controlled adjuvant release, aiming to avoid excessive cytokine responses while preserving efficacy.5
The Future of Inhalable Nanovaccines
Future research will likely see inhalable nanovaccines targeting a broader range of diseases, from RSV to antimicrobial-resistant pathogens. Emerging directions include the use of AI-based models to optimize nanoparticle design, multivalent formulations that deliver several antigens simultaneously, and thermostable formulations in powder form to support use in low-resource or emergency settings.7,8
Inhalable nanovaccines represent an evolving area of vaccine technology. By enabling mucosal immune responses and offering needle-free administration, they may expand access to immunization and improve outcomes for respiratory diseases. Although formulation and distribution challenges remain, continued research and cross-sector collaboration may support the broader implementation of inhalable vaccine platforms as part of future public health strategies.
If you want to learn more about inhalable nanovaccines and related advances in drug delivery, immunology, and nanotechnology, subscribe to our expert-curated Nanomedicine Newsletter.
References and Further Reading
- Jiang, A. Y. et al. (2024). Zwitterionic Polymer-Functionalized Lipid Nanoparticles for the Nebulized Delivery of mRNA. Journal of the American Chemical Society. DOI:10.1021/jacs.4c11347. https://pubs.acs.org/doi/full/10.1021/jacs.4c11347
- Li, H. et al. (2025). Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy. Signal Transduction and Targeted Therapy, 10(1), 1-15. DOI:10.1038/s41392-025-02191-1. https://www.nature.com/articles/s41392-025-02191-1
- Zheng, B. et al. (2021). Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chemical Engineering Journal, 418, 129392. DOI:10.1016/j.cej.2021.129392. https://www.sciencedirect.com/science/article/pii/S1385894721009803
- Inhalable therapy uses mussel-inspired nanoparticles to target lung cancer cells. (2025). Phys.org. https://phys.org/news/2025-01-inhalable-therapy-mussel-nanoparticles-lung.html
- Wang, S. et al. (2024). Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants. Journal of Nanobiotechnology, 22, 76. DOI:10.1186/s12951-024-02345-3. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-024-02345-3
- Kiyono, H., & Ernst, P. B. (2025). Nasal vaccines for respiratory infections. Nature, 641(8062), 321-330. DOI:10.1038/s41586-025-08910-6. https://www.nature.com/articles/s41586-025-08910-6
- Sukumaran, P. (2025). Novel NanoVaccines Against Emerging Isolates of Avian Influenza. Nanovaccine Institute, Iowa State University. https://nanovaccine.iastate.edu/novel-nanovaccines-against-emerging-isolates-of-avian-influenza/
- Saleh, M. et al. (2025). Revolutionizing Nanovaccines: A New Era of Immunization. Vaccines, 13(2), 126. DOI:10.3390/vaccines13020126. https://www.mdpi.com/2076-393X/13/2/126
News
Scientists Melt Cancer’s Hidden “Power Hubs” and Stop Tumor Growth
Researchers discovered that in a rare kidney cancer, RNA builds droplet-like hubs that act as growth control centers inside tumor cells. By engineering a molecular switch to dissolve these hubs, they were able to halt cancer [...]
Platelet-inspired nanoparticles could improve treatment of inflammatory diseases
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness. Scientists have found a way to improve the performance of brain-computer interface (BCI) electrodes by delivering anti-inflammatory drugs directly [...]
After 150 years, a new chapter in cancer therapy is finally beginning
For decades, researchers have been looking for ways to destroy cancer cells in a targeted manner without further weakening the body. But for many patients whose immune system is severely impaired by chemotherapy or radiation, [...]
Older chemical libraries show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, University of California San Diego scientists and an international team of [...]
Lower doses of immunotherapy for skin cancer give better results, study suggests
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National [...]
Researchers highlight five pathways through which microplastics can harm the brain
Microplastics could be fueling neurodegenerative diseases like Alzheimer's and Parkinson's, with a new study highlighting five ways microplastics can trigger inflammation and damage in the brain. More than 57 million people live with dementia, [...]
Tiny Metal Nanodots Obliterate Cancer Cells While Largely Sparing Healthy Tissue
Scientists have developed tiny metal-oxide particles that push cancer cells past their stress limits while sparing healthy tissue. An international team led by RMIT University has developed tiny particles called nanodots, crafted from a metallic compound, [...]
Gold Nanoclusters Could Supercharge Quantum Computers
Researchers found that gold “super atoms” can behave like the atoms in top-tier quantum systems—only far easier to scale. These tiny clusters can be customized at the molecular level, offering a powerful, tunable foundation [...]
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
WASHINGTON -- A single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer, researchers reported Wednesday. HPV, or human papillomavirus, is very common and spread [...]
New technique overcomes technological barrier in 3D brain imaging
Scientists at the Swiss Light Source SLS have succeeded in mapping a piece of brain tissue in 3D at unprecedented resolution using X-rays, non-destructively. The breakthrough overcomes a long-standing technological barrier that had limited [...]
Scientists Uncover Hidden Blood Pattern in Long COVID
Researchers found persistent microclot and NET structures in Long COVID blood that may explain long-lasting symptoms. Researchers examining Long COVID have identified a structural connection between circulating microclots and neutrophil extracellular traps (NETs). The [...]
This Cellular Trick Helps Cancer Spread, but Could Also Stop It
Groups of normal cbiells can sense far into their surroundings, helping explain cancer cell migration. Understanding this ability could lead to new ways to limit tumor spread. The tale of the princess and the [...]
New mRNA therapy targets drug-resistant pneumonia
Bacteria that multiply on surfaces are a major headache in health care when they gain a foothold on, for example, implants or in catheters. Researchers at Chalmers University of Technology in Sweden have found [...]
Current Heart Health Guidelines Are Failing To Catch a Deadly Genetic Killer
New research reveals that standard screening misses most people with a common inherited cholesterol disorder. A Mayo Clinic study reports that current genetic screening guidelines overlook most people who have familial hypercholesterolemia, an inherited disorder that [...]
Scientists Identify the Evolutionary “Purpose” of Consciousness
Summary: Researchers at Ruhr University Bochum explore why consciousness evolved and why different species developed it in distinct ways. By comparing humans with birds, they show that complex awareness may arise through different neural architectures yet [...]
Novel mRNA therapy curbs antibiotic-resistant infections in preclinical lung models
Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. The findings, published in Nature Biotechnology, show that in [...]
